Multiomic Health valuation, funding and investors
Multiomic Health works in precision medicine solutions development, based in London, United Kingdom. Founded in 2021, it has about 13 employees.
- Last round
- Seed · $6.20M · May 2023
- Valuation at last round
- $37.9M · implied
- Headcount
- 13 · shrinking
- Grade
- C
- Founded
- 2021
Multiomic Health valuation today
VCMC values Multiomic Health at $10.4M today, with a range of $5.65M to $23.2M and a grade of C. The valuation starts from its last funding round, a seed round in May 2023.
Valuation by date (72 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2021 | $10.7M | $3.89M – $29.3M | $11.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $10.8M | $3.93M – $29.6M | $12.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $10.9M | $3.96M – $29.9M | $12.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $11.0M | $3.99M – $30.1M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $11.1M | $4.03M – $30.4M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2021 | $11.2M | $4.07M – $30.7M | $12.3M (+10%) | before first round | – | unknown | D | 0% |
| 1 Jul 2021 | $11.3M | $4.10M – $31.0M | $12.4M (+10%) | before first round | – | unknown | D | 0% |
| 1 Aug 2021 | $11.4M | $4.14M – $31.2M | $12.5M (+10%) | before first round | – | unknown | D | 0% |
| 1 Sep 2021 | $11.5M | $4.18M – $31.5M | $12.6M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2021 | $11.6M | $4.22M – $31.8M | $12.7M (+10%) | before first round | – | unknown | D | 0% |
| 1 Nov 2021 | $11.7M | $4.25M – $32.1M | $12.8M (+10%) | before first round | – | unknown | D | 0% |
| 1 Dec 2021 | $11.8M | $4.29M – $32.4M | $12.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2022 | $11.9M | $4.33M – $32.7M | $13.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2022 | $12.0M | $4.36M – $32.9M | $13.1M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2022 | $12.1M | $4.39M – $33.2M | $13.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2022 | $11.8M | $4.28M – $32.3M | $12.8M (+9%) | before first round | 13 | unknown | D | 0% |
| 1 May 2022 | $11.8M | $4.31M – $32.5M | $12.9M (+9%) | before first round | 13 | unknown | D | 0% |
| 1 Jun 2022 | $11.9M | $4.34M – $32.8M | $13.0M (+9%) | before first round | 13 | unknown | D | 0% |
| 1 Jul 2022 | $12.0M | $4.38M – $33.0M | $13.1M (+9%) | before first round | 13 | unknown | D | 0% |
| 1 Aug 2022 | $12.1M | $4.41M – $33.3M | $13.2M (+9%) | before first round | 13 | unknown | D | 0% |
| 1 Sep 2022 | $12.2M | $4.44M – $33.5M | $13.3M (+9%) | before first round | 13 | unknown | D | 0% |
| 1 Oct 2022 | $12.3M | $4.47M – $33.8M | $13.4M (+9%) | before first round | 13 | unknown | D | 0% |
| 1 Nov 2022 | $12.4M | $4.51M – $34.0M | $13.5M (+9%) | before first round | 13 | unknown | D | 0% |
| 1 Dec 2022 | $12.5M | $4.54M – $34.3M | $13.6M (+9%) | before first round | 13 | unknown | D | 0% |
| 1 Jan 2023 | $12.6M | $4.58M – $34.5M | $13.7M (+9%) | before first round | 13 | unknown | D | 0% |
| 1 Feb 2023 | $12.7M | $4.61M – $34.8M | $13.8M (+9%) | before first round | 13 | flat | D | 0% |
| 1 Mar 2023 | $12.7M | $4.64M – $35.0M | $13.9M (+9%) | before first round | 13 | flat | D | 0% |
| 1 Apr 2023 | $12.8M | $4.68M – $35.3M | $14.0M (+9%) | before first round | 13 | flat | D | 0% |
| 1 May 2023 | $12.9M | $4.71M – $35.5M | $14.1M (+9%) | before first round | 13 | flat | D | 0% |
| 5 May 2023 | $38.0M | $24.9M – $115M | $75.8M (+100%) | after a round | 13 | flat | C | 0% |
| 1 Jun 2023 | $40.0M | $24.9M – $115M | $75.8M (+90%) | after a round | 13 | flat | C | 0% |
| 1 Jul 2023 | $42.3M | $24.9M – $115M | $75.8M (+79%) | after a round | 13 | flat | C | 0% |
| 1 Aug 2023 | $44.9M | $24.9M – $115M | $75.8M (+69%) | after a round | 13 | flat | C | 0% |
| 1 Sep 2023 | $47.6M | $24.9M – $115M | $75.8M (+59%) | after a round | 13 | flat | C | 0% |
| 1 Oct 2023 | $50.4M | $24.9M – $115M | $75.8M (+50%) | after a round | 13 | unknown | C | 0% |
| 1 Nov 2023 | $53.5M | $24.9M – $115M | $75.8M (+42%) | after a round | 13 | flat | C | 0% |
| 1 Dec 2023 | $56.6M | $24.9M – $115M | $75.8M (+34%) | after a round | 13 | flat | C | 0% |
| 1 Jan 2024 | $60.0M | $24.9M – $115M | $75.8M (+26%) | after a round | 13 | flat | C | 0% |
| 1 Feb 2024 | $63.7M | $24.9M – $115M | $75.8M (+19%) | after a round | 13 | flat | C | 0% |
| 1 Mar 2024 | $72.1M | $27.1M – $125M | $82.4M (+14%) | after a round | 19 | growing | C | 0% |
| 1 Apr 2024 | $77.0M | $27.1M – $125M | $82.4M (+7%) | after a round | 19 | growing | C | 0% |
| 1 May 2024 | $82.1M | $27.1M – $125M | $82.4M (0%) | after a round | 19 | growing | C | 0% |
| 1 Jun 2024 | $82.4M | $27.2M – $125M | $82.4M (0%) | after a round | 19 | growing | C | 0% |
| 1 Jul 2024 | $82.4M | $27.3M – $125M | $82.4M (0%) | after a round | 19 | growing | C | 0% |
| 1 Aug 2024 | $82.4M | $27.4M – $125M | $82.4M (0%) | after a round | 19 | growing | C | 0% |
| 1 Sep 2024 | $83.4M | $27.9M – $127M | $83.4M (0%) | after a round | 20 | growing | C | 0% |
| 1 Oct 2024 | $83.4M | $28.0M – $127M | $83.4M (0%) | after a round | 20 | growing | C | 0% |
| 1 Nov 2024 | $83.4M | $28.1M – $127M | $83.4M (0%) | after a round | 20 | growing | C | 0% |
| 1 Dec 2024 | $83.4M | $28.2M – $127M | $83.4M (0%) | after a round | 20 | growing | C | 0% |
| 1 Jan 2025 | $83.4M | $28.3M – $127M | $83.4M (0%) | after a round | 20 | growing | C | 0% |
| 1 Feb 2025 | $83.4M | $28.5M – $127M | $83.4M (0%) | after a round | 20 | growing | C | 0% |
| 1 Mar 2025 | $83.4M | $28.6M – $127M | $83.4M (0%) | after a round | 20 | growing | C | 0% |
| 1 Apr 2025 | $83.4M | $28.7M – $127M | $83.4M (0%) | after a round | 20 | growing | C | 0% |
| 1 May 2025 | $83.4M | $15.1M – $127M | $83.4M (0%) | after a round | 20 | flat | D | 0% |
| 1 Jun 2025 | $83.4M | $14.3M – $127M | $82.9M (-1%) | after a round | 20 | flat | D | 0% |
| 1 Jul 2025 | $83.4M | $13.7M – $127M | $82.3M (-1%) | after a round | 20 | flat | D | 0% |
| 1 Aug 2025 | $85.1M | $14.6M – $130M | $84.1M (-1%) | after a round | 22 | up | D | 0% |
| 1 Sep 2025 | $85.1M | $14.0M – $130M | $83.7M (-2%) | after a round | 22 | up | D | 0% |
| 1 Oct 2025 | $85.1M | $12.0M – $130M | $83.0M (-3%) | after a round | 22 | flat | D | 0% |
| 1 Nov 2025 | $85.1M | $11.4M – $130M | $82.5M (-3%) | after a round | 22 | flat | D | 0% |
| 1 Dec 2025 | $83.4M | $10.6M – $127M | $79.8M (-4%) | after a round | 20 | flat | D | 0% |
| 1 Jan 2026 | $83.4M | $10.1M – $127M | $79.3M (-5%) | after a round | 20 | flat | D | 0% |
| 1 Feb 2026 | $83.4M | $9.59M – $127M | $78.8M (-6%) | after a round | 20 | flat | D | 0% |
| 1 Mar 2026 | $83.4M | $9.16M – $127M | $77.9M (-7%) | after a round | 20 | flat | D | 0% |
| 1 Apr 2026 | $83.4M | $8.71M – $127M | $77.4M (-7%) | after a round | 20 | flat | D | 0% |
| 1 May 2026 | $81.3M | $8.29M – $126M | $73.2M (-10%) | after a round | 20 | flat | D | 2% |
| 1 Jun 2026 | $34.9M | $7.88M – $90.8M | $27.2M (-22%) | after a round | 20 | flat | D | 55% |
| 1 Jul 2026 | $34.0M | $7.50M – $89.7M | $26.6M (-22%) | after a round | 20 | flat | D | 55% |
| 1 Aug 2026 | $33.1M | $7.13M – $88.6M | $25.9M (-22%) | after a round | 20 | flat | D | 55% |
| 1 Sep 2026 | $32.2M | $6.77M – $87.5M | $25.3M (-22%) | after a round | 20 | flat | D | 55% |
| 1 Oct 2026 | $10.7M | $5.86M – $23.8M | $6.69M (-38%) | after a round | 13 | shrinking | C | 97% |
| 24 Oct 2026 | $10.4M | $5.65M – $23.2M | $6.47M (-38%) | after a round | 13 | shrinking | C | 97% |
Key facts about Multiomic Health
- Founded
- 2021
- Headquarters
- London, United Kingdom
- Employees
- about 13 -41% in a year
- Total raised
- $6.2M
- Funding rounds
- 1
- Last round
- Seed May 2023
Multiomic Health was founded in 2021 by Alasdair Thong and Robert Thong.
Multiomic Health funding history
Multiomic Health has 1 funding round on record, from May 2023 to May 2023, $6.2M in total. None disclosed a valuation.
Seed 4 May 2023
Led by Hoxton Ventures; with Ada Ventures, MMC, Verve Ventures, Fifty Years, HOF Capital.
Sources: multiomic.health, multiomic.health, finsmes.com and 4 more
$6.2M
Multiomic Health investors
6 investors have backed Multiomic Health; Hoxton Ventures led at least one round.
What Multiomic Health does
Multiomic Health works in biotechnology, with 15 recorded offerings and customers in healthcare and pharmaceuticals.
Multiomic Health Limited is a UK company engaged in computational systems biology and precision medicine. The company develops and commercializes data assets for metabolic syndrome-related conditions, including metabolic syndrome, type 2 diabetes, chronic kidney disease, and non-alcoholic fatty liver. Multiomic Health operates as a computational systems biology business, utilizing AI-enabled data science and experimental biology to identify patient subpopulations with distinct molecular-level disease drivers. The company also manages a drug discovery and development pipeline, including companion diagnostics and laboratory-developed tests, and collaborates with pharmaceutical industry partners and laboratory service providers to implement its diagnostics.
Description from Veridion's company data.
Products and services
- Precision Medicine Solutions Development
- AI-Enabled Clinical Data Analytics
- Patient Endotype Identification and Modeling
- Drug Discovery and Repositioning
- Precision Therapeutics Development
- Companion Diagnostic Development
- Laboratory-Developed Diagnostic Implementation
- In Vitro Diagnostic Development
- Metabolic Syndrome Therapeutics Commercialization
- Cardiovascular Disease Therapeutics Development
- Diabetic Nephropathy Therapeutics Development
- Diabetic Neuropathy Therapeutics Development
- Diabetic Retinopathy Therapeutics Development
- Omics Data Integration and Analysis
- Clinical Trial Design and Optimization
Markets
- Healthcare
- Pharmaceuticals
Technology
- AI-Enabled Predictive Analytics
- Computational Systems Biology Modeling
- Data Lake for Omics and Clinical Data
- Laboratory-Developed Tests for Companion Diagnostics
- In Vitro Diagnostics for Companion Diagnostics
Certifications
- GDPR compliant
Business model
- Business-to-Business
- Manufacturing
- Enterprise
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Multiomic Health
What is Multiomic Health worth?
Valuation $10.4M (range $5.65M to $23.2M), as of 24 Oct 2026.
Has Multiomic Health raised money?
Multiomic Health has 1 funding round on record, from May 2023 to May 2023, $6.2M in total. None disclosed a valuation.
Who has invested in Multiomic Health?
Hoxton Ventures, Ada Ventures, Fifty Years, HOF Capital, MMC and Verve Ventures. Lead investors include Hoxton Ventures.
How many people work at Multiomic Health?
About 13, down 41% over the last year. Headcount rose from 13 in Mar 2022 to 22 in Jul 2025, then fell to 13 in Sep 2026.
What does Multiomic Health do?
Multiomic Health works in biotechnology, with 15 recorded offerings and customers in healthcare and pharmaceuticals. Its main offerings are precision medicine solutions development, AI-Enabled clinical data analytics and patient endotype identification and modeling.
When was Multiomic Health founded, and where is it based?
Multiomic Health was founded in 2021 and is based in London, United Kingdom. It has about 13 employees, down 41% over the last year.